Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database

Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS

(2019) Huan-huan Ji et al.   CLINICAL DRUG INVESTIGATION

Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis

(2019) Xiaoying Sun et al.   BMC CANCER

Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis

(2019) H. K. Akturk et al.   DIABETIC MEDICINE

Immune-Related Adverse Events: A Case-Based Approach

(2019) Caoilfhionn Connolly et al.   Frontiers in Oncology

Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases

(2019) Kazuyo Shimada et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Factors Associated With Immune Checkpoint Inhibitor–Related Myocarditis

(2019) Yoshito Zamami et al.   JAMA Oncology

Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database

(2019) Kenichiro Sato et al.   JOURNAL OF NEURO-ONCOLOGY

Analysis of drug-induced hearing loss by using a spontaneous reporting system database

(2019) Mizuki Tanaka et al.   PLoS One

Propensity score‐adjusted three‐component mixture model for drug‐drug interaction data mining in FDA Adverse Event Reporting System

(2019) Xueying Wang et al.   STATISTICS IN MEDICINE

Evaluating large-scale propensity score performance through real-world and synthetic data experiments

(2018) Yuxi Tian et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Endocrine toxicity of cancer immunotherapy targeting immune checkpoints

(2018) Lee-Shing Chang et al.   ENDOCRINE REVIEWS

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

(2018) Cheng Xu et al.   BMJ-British Medical Journal

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

(2017) D. Makarious et al.   EUROPEAN JOURNAL OF CANCER

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

(2017) Omar Abdel-Rahman et al.   Expert Review of Anticancer Therapy

Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

(2017) David J. Byun et al.   Nature Reviews Endocrinology

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

(2017) Peng-Fei Wang et al.   Frontiers in Pharmacology

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade

(2016) Patrizio Caturegli et al.   AMERICAN JOURNAL OF PATHOLOGY

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy

(2016) Thomas K. Eigentler et al.   CANCER TREATMENT REVIEWS

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma

(2016) Yudai Okano et al.   ENDOCRINE JOURNAL

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

(2016) V.R. Belum et al.   EUROPEAN JOURNAL OF CANCER

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

(2016) F Stephen Hodi et al.   LANCET ONCOLOGY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events

(2016) Elisa González-Rodríguez et al.   ONCOLOGIST

Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events

(2016) Sayaka Sasaoka et al.   PLoS One

Assessment of the Risk of Suicide-Related Events Induced by Concomitant Use of Antidepressants in Cases of Smoking Cessation Treatment with Varenicline and Assessment of Latent Risk by the Use of Varenicline

(2016) Hayato Akimoto et al.   PLoS One

Characterizing treatment pathways at scale using the OHDSI network

(2016) George Hripcsak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis

(2016) Xi Zhang et al.   Drug Design Development and Therapy

A Pharmacovigilance Approach for Post-Marketing in Japan Using the Japanese Adverse Drug Event Report (JADER) Database and Association Analysis

(2016) Masakazu Fujiwara et al.   PLoS One

Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports

(2016) Noha Abdel-Wahab et al.   PLoS One

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database

(2015) Yukiya Suzuki et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data

(2015) Ryogo Umetsu et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Toxicities of Immunotherapy for the Practitioner

(2015) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toxicity Patterns With Immunomodulating Antibodies and Their Combinations

(2015) John B.A.G. Haanen et al.   SEMINARS IN ONCOLOGY

Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases

(2015) Kaori Nomura et al.   Drug Design Development and Therapy

Association Patterns in Open Data to Explore Ciprofloxacin Adverse Events

(2015) P. Yildirim   Applied Clinical Informatics

Therapeutic use of anti-CTLA-4 antibodies

(2014) C. U. Blank et al.   INTERNATIONAL IMMUNOLOGY

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

Illustration of the Weibull Shape Parameter Signal Detection Tool Using Electronic Healthcare Record Data

(2013) Odile Sauzet et al.   DRUG SAFETY

At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy

(2013) Margaret K. Callahan et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Ipilimumab-induced autoimmune adrenalitis

(2013) Le Min et al.   Lancet Diabetes & Endocrinology

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database

(2011) E. Raschi et al.   ACTA DIABETOLOGICA

Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database

(2011) Jean-Louis Montastruc et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Mining multi-item drug adverse effect associations in spontaneous reporting systems

(2010) Rave Harpaz et al.   BMC BIOINFORMATICS

An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database

(2010) Hsin-wei Wang et al.   DRUG SAFETY

An automated technique for identifying associations between medications, laboratory results and problems

(2010) Adam Wright et al.   JOURNAL OF BIOMEDICAL INFORMATICS

Quantitative signal detection using spontaneous ADR reporting

(2009) A. Bate et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding

(2008) Fleur Grégoire et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY